FibroGen, Inc(FGEN)

Description: FibroGen, Inc. operates as a research-based biopharmaceutical company in the United States. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was incorporated in 1993 and is headquartered in San Francisco, California.

---

Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Monoclonal Antibody Kidney Disease Anemia Pancreatic Cancer Chronic Kidney Disease Collagen Idiopathic Pulmonary Fibrosis Blindness Pulmonary Fibrosis Liver Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Cornea Roxadustat Hypoxia Inducible Factors Acetic Acids Corneal Blindness Pamrevlumab Research Based Biopharmaceutical Treatment Of Anemia In Chronic Kidney Disease

---

Home Page: www.fibrogen.com

FGEN Technical Analysis

409 Illinois Street
San Francisco, CA 94158
United States
Phone: 415 978 1200

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)